Join the Migraine Prophylaxis group to help and get support from people like you.
Migraine Prophylaxis News (Page 3)
No Causal Association Seen for Meniere Disease, Migraine
MONDAY, June 3, 2024 – Migraine is not a risk factor for Meniere disease (MD), nor is MD a risk factor for migraine, according to a study published online May 8 in Frontiers in Neurology. Kangjia...
Stroke, Migraine, Alzheimer's: Climate Change Will Likely Make Them Worse
THURSDAY, May 16, 2024 – Climate change is likely to make brain conditions like stroke, migraine, Alzheimer’s disease, epilepsy and multiple sclerosis even worse, a new review warns. The potential e...
Targeted Diagnostic Botox Injections Can Identify Trigger Sites for Migraine
THURSDAY, May 9, 2024 – Diagnostic targeted Botox injections have high positive predictive value for migraine trigger site localization, according to a study published in the May issue of Plastic...
FDA Approves Qulipta (atogepant) Oral CGRP Receptor Antagonist for the Preventive Treatment of Migraine
NORTH CHICAGO, Ill., Sept. 28, 2021 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Qulipta (atogepant) for the preventive treatment of...
FDA Approves Biohaven's Nurtec ODT (rimegepant) for Preventative Treatment of Migraine
Nurtec ODT 75 mg is the first oral CGRP antagonist approved to prevent migraine Nurtec ODT 75 mg is now the only migraine medication approved to both treat acute migraine attacks and help prevent...
FDA Approves Vyepti (eptinezumab-jjmr) Intravenous Injection for the Preventive Treatment of Migraine
Valby, Denmark, February 22, 2020 – H. Lundbeck A/S today announced that Vyepti (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of m...
Teva Announces FDA Approval of Ajovy (fremanezumab-vfrm) Injection Autoinjector
PARSIPPANY, N.J.--(BUSINESS WIRE) January 28, 2020 – Teva Pharmaceuticals USA, Inc. an affiliate ofTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Food and Drug...
FDA Approves Emgality (galcanezumab-gnlm) for the Preventive Treatment of Migraine in Adults
INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg i...
FDA Approves Ajovy (fremanezumab-vfrm) for Preventive Treatment of Migraine
September 14, 2018 – Today, the US Food and Drug Administration (FDA) approved Ajovy (fremanezumab-vfrm) for the preventive treatment of migraine in adults. Ajovy is the second FDA-approved...
FDA Approves Aimovig (erenumab-aooe) as a Preventive Treatment for Migraine
May 17, 2018 – The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly...
FDA Approves Topamax for Migraine Prevention in Adolescents
March 28, 2014 – Today, the U.S. Food and Drug Administration approved Topamax (topiramate) for prevention (prophylaxis) of migraine headaches in adolescents ages 12 to 17. This is the first FDA...
FDA Medwatch Alert: Valproate Anti-Seizure Products: Drug Safety Communication - Contraindicated for Pregnant Women for Prevention of Migraine Headaches
Including valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic acid (Depakene and Stavzor), and their generics ISSUE: FDA is advising health care...
Further information
Related condition support groups
Related drug support groups
clonazepam, lisinopril, metoprolol, bupropion, amitriptyline, amlodipine, propranolol, Topamax, pregabalin, view more... lamotrigine, Depakote, atenolol, baclofen, topiramate, clonidine, nortriptyline, Botox, Emgality, Aimovig, erenumab, Ajovy, verapamil, Qulipta, nifedipine, Nurtec ODT